Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development
Reference number: GID-TA10592
Expected publication date: TBC
The Topic Selection Oversight Panel concluded that as a new formulation of an already existing agent, Pertuzumab–trastuzumab with chemotherapy is not a significant licence extension to progress through to Technology Appraisal assessment. The appraisal is therefore suspended from the NICE work programme. Access to this treatment is managed through NHS England and Improvement routine commissioning.